Cargando…
Flares in patients with systemic lupus erythematosus
OBJECTIVE: SLE is characterized by relapses and remissions. We aimed to describe the frequency, type and time to flare in a cohort of SLE patients. METHODS: SLE patients with one or more ‘A’ or ‘B’ BILAG-2004 systems meeting flare criteria (‘new’ or ‘worse’ items) and requiring an increase in immuno...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517882/ https://www.ncbi.nlm.nih.gov/pubmed/33325488 http://dx.doi.org/10.1093/rheumatology/keaa777 |
_version_ | 1784584101738577920 |
---|---|
author | McElhone, Kathleen Abbott, Janice Hurley, Margaret Burnell, Jane Lanyon, Peter Rahman, Anisur Yee, Chee-Seng Akil, Mohammed Bruce, Ian N Ahmad, Yasmeen Gordon, Caroline Teh, Lee-Suan |
author_facet | McElhone, Kathleen Abbott, Janice Hurley, Margaret Burnell, Jane Lanyon, Peter Rahman, Anisur Yee, Chee-Seng Akil, Mohammed Bruce, Ian N Ahmad, Yasmeen Gordon, Caroline Teh, Lee-Suan |
author_sort | McElhone, Kathleen |
collection | PubMed |
description | OBJECTIVE: SLE is characterized by relapses and remissions. We aimed to describe the frequency, type and time to flare in a cohort of SLE patients. METHODS: SLE patients with one or more ‘A’ or ‘B’ BILAG-2004 systems meeting flare criteria (‘new’ or ‘worse’ items) and requiring an increase in immunosuppression were recruited from nine UK centres and assessed at baseline and monthly for 9 months. Subsequent flares were defined as: severe (any ‘A’ irrespective of number of ‘B’ flares), moderate (two or more ‘B’ without any ‘A’ flares) and mild (one ‘B’). RESULTS: Of the 100 patients, 94% were female, 61% White Caucasians, mean age (s.d.) was 40.7 years (12.7) and mean disease duration (s.d.) was 9.3 years (8.1). A total of 195 flares re-occurred in 76 patients over 781 monthly assessments (flare rate of 0.25/patient-month). There were 37 severe flares, 32 moderate flares and 126 mild flares. By 1 month, 22% had a mild/moderate/severe flare and 22% had a severe flare by 7 months. The median time to any ‘A’ or ‘B’ flare was 4 months. Severe/moderate flares tended to be in the system(s) affected at baseline, whereas mild flares could affect any system. CONCLUSION: . In a population with active SLE we observed an ongoing rate of flares from early in the follow-up period with moderate–severe flares being due to an inability to fully control the disease. This real-world population study demonstrates the limitations of current treatments and provides a useful reference population from which to inform future clinical trial design. |
format | Online Article Text |
id | pubmed-8517882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-85178822021-10-15 Flares in patients with systemic lupus erythematosus McElhone, Kathleen Abbott, Janice Hurley, Margaret Burnell, Jane Lanyon, Peter Rahman, Anisur Yee, Chee-Seng Akil, Mohammed Bruce, Ian N Ahmad, Yasmeen Gordon, Caroline Teh, Lee-Suan Rheumatology (Oxford) Clinical Science OBJECTIVE: SLE is characterized by relapses and remissions. We aimed to describe the frequency, type and time to flare in a cohort of SLE patients. METHODS: SLE patients with one or more ‘A’ or ‘B’ BILAG-2004 systems meeting flare criteria (‘new’ or ‘worse’ items) and requiring an increase in immunosuppression were recruited from nine UK centres and assessed at baseline and monthly for 9 months. Subsequent flares were defined as: severe (any ‘A’ irrespective of number of ‘B’ flares), moderate (two or more ‘B’ without any ‘A’ flares) and mild (one ‘B’). RESULTS: Of the 100 patients, 94% were female, 61% White Caucasians, mean age (s.d.) was 40.7 years (12.7) and mean disease duration (s.d.) was 9.3 years (8.1). A total of 195 flares re-occurred in 76 patients over 781 monthly assessments (flare rate of 0.25/patient-month). There were 37 severe flares, 32 moderate flares and 126 mild flares. By 1 month, 22% had a mild/moderate/severe flare and 22% had a severe flare by 7 months. The median time to any ‘A’ or ‘B’ flare was 4 months. Severe/moderate flares tended to be in the system(s) affected at baseline, whereas mild flares could affect any system. CONCLUSION: . In a population with active SLE we observed an ongoing rate of flares from early in the follow-up period with moderate–severe flares being due to an inability to fully control the disease. This real-world population study demonstrates the limitations of current treatments and provides a useful reference population from which to inform future clinical trial design. Oxford University Press 2020-12-16 /pmc/articles/PMC8517882/ /pubmed/33325488 http://dx.doi.org/10.1093/rheumatology/keaa777 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Science McElhone, Kathleen Abbott, Janice Hurley, Margaret Burnell, Jane Lanyon, Peter Rahman, Anisur Yee, Chee-Seng Akil, Mohammed Bruce, Ian N Ahmad, Yasmeen Gordon, Caroline Teh, Lee-Suan Flares in patients with systemic lupus erythematosus |
title | Flares in patients with systemic lupus erythematosus |
title_full | Flares in patients with systemic lupus erythematosus |
title_fullStr | Flares in patients with systemic lupus erythematosus |
title_full_unstemmed | Flares in patients with systemic lupus erythematosus |
title_short | Flares in patients with systemic lupus erythematosus |
title_sort | flares in patients with systemic lupus erythematosus |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517882/ https://www.ncbi.nlm.nih.gov/pubmed/33325488 http://dx.doi.org/10.1093/rheumatology/keaa777 |
work_keys_str_mv | AT mcelhonekathleen flaresinpatientswithsystemiclupuserythematosus AT abbottjanice flaresinpatientswithsystemiclupuserythematosus AT hurleymargaret flaresinpatientswithsystemiclupuserythematosus AT burnelljane flaresinpatientswithsystemiclupuserythematosus AT lanyonpeter flaresinpatientswithsystemiclupuserythematosus AT rahmananisur flaresinpatientswithsystemiclupuserythematosus AT yeecheeseng flaresinpatientswithsystemiclupuserythematosus AT akilmohammed flaresinpatientswithsystemiclupuserythematosus AT bruceiann flaresinpatientswithsystemiclupuserythematosus AT ahmadyasmeen flaresinpatientswithsystemiclupuserythematosus AT gordoncaroline flaresinpatientswithsystemiclupuserythematosus AT tehleesuan flaresinpatientswithsystemiclupuserythematosus |